Abstract
Review of: Medical and Healthcare products Regulatory Agency. Denosumab for giant cell tumor of bone: risk of clinically significant hypercalcaemia following discontinuation. Drug Safety Update 2018;11(11);2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have